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Abstract: This article describes the theoretical and pragmatic development of a patient-centred
intervention for patients with atrial fibrillation (AF). Theoretical models (Common Sense Model,
Necessity-Concerns Framework), clinical frameworks, and AF patient feedback contributed to
the design of a one-off hour-long behaviour-change intervention package. Intervention materials
consisted of a DVD, educational booklet, diary and worksheet, which were patient-centred and easy
to administer. The intervention was evaluated within a randomised controlled trial. Several “active
theoretical ingredients” were identified (for e.g., where patients believed their medication was less
harmful they spent more time within the therapeutic range (TTR), with general harm scores predicting
TTR at 6 months). Allowing for social comparison and adopting behaviour change techniques enabled
accurate patient understanding of their condition and medication. The process of developing the
intervention using theory-derived content and evaluation tools allowed a greater understanding of
the mechanisms by which this intervention was successful. Alleviating concerns about treatment
medication by educating patients can help to improve adherence. This process of intervention
development could be adopted for a range of chronic illnesses and treatments. Critical elements
should include the use of: (1) clinical guidelines; (2) appropriate theoretical models; (3) patient input;
and (4) appropriate evaluation tools.
Keywords: common-sense model; intervention; necessity-concerns; atrial fibrillation; anticoagulation
1. Introduction
Complex interventions aiming to change health behaviour contain several interacting components.
They may target numerous factors such as patient perceptions, diet, lifestyle, cognitive capacity,
physical capability, understanding, knowledge and the behavioural skill-set to perform the required
health behaviour [1]. These types of interventions are widely used within public health and
clinical practice yet their design and evaluation have been criticised as using a “black box”
approach, whereby we are unable to determine how and why interventions work due to incomplete
reporting and documentation of process [2]. The Medical Research Council (MRC) framework
for the development and evaluation of complex interventions includes pre-clinical and theoretical
development [3]. However, the literature surrounding intervention development is still very limited,
thus whilst trials report outcomes of their evaluative process, little is known about the mechanisms of
successful interventions.
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A recent Cochrane systematic review suggested the need for a comprehensive behavioural
intervention for patients with atrial fibrillation (AF) [4]. This patient group, with a high risk of
stroke, has received little attention regarding theory-based intervention development. Patients with
AF are prescribed oral anticoagulation (OAC) to reduce their risk of stroke, and their adherence
to treatment and recommendations can be objectively monitored over time [5]. This group is in
particular need of theoretically-driven educational materials as evidence suggests they have little
knowledge of their condition or treatment [6–8], poor adherence to medication and associated
lifestyle recommendations [9,10], high levels of anxiety and depression [11,12] and inaccurate illness
representations [13].
This article will describe the theoretical and pragmatic development of a patient-centred
intervention for patients with atrial fibrillation (AF). The process undertaken to design and
develop the TRial of an Educational Intervention for patients with ATrial Fibrillation (TREAT)
(ISRCTN93952605) [14] intervention will be used as an example of the intervention design and
evaluation process. The TREAT intervention has recently been tested in a randomised controlled trial.
The main results have been reported [15].
1.1. Intervention Development Process
The development of the intervention was a collaborative process involving health psychologists,
cardiologists, nurses and patients. Clinical guidelines [3,16–18] and theoretical models [19,20] provided
the basic content for the educational materials. A parallel patient feedback process ensured the final
intervention was patient-centred (see Figure 1). The development process was documented at all
stages to ensure it was explicit and replicable.
1.2. Theoretical Approach
1.2.1. Application of the Necessity-Concerns Framework
Patient’s beliefs about their prescribed medication can play an important role in the
decision to adhere to the required medication regimen and associated lifestyle recommendations.
The “Necessity-Concerns Framework” suggests that patients hold beliefs about medication, including
its necessity and concerns about dependence and long-term toxicity. It also describes general beliefs
about medication, such as its potential to be addictive, harmful, and over-prescribed by doctors. These
beliefs, and the way in which patients balance their concern about medications with their beliefs
about the necessity for the medication to control their condition, have been widely used in predicting
adherence in a variety of chronic conditions including rheumatoid arthritis [21], asthma [22], type II
diabetes [23] and depression [24].
Adherence to medication can be both intentional and unintentional. When unintentional,
non-adherence can refer to a person’s ability to take their tablets, which is often due to memory
impairment. This can be rectified by providing memory aids, dosettes and daily routines (Table 1).
However, patients who intentionally choose not to take their medication based on individual
motivations and/or beliefs may require a more complex intervention. Patients may report either
intentional or unintentional non-adherence or both, and indeed the two concepts may overlap (e.g.,
if an individual believes medication is unnecessary, they may be less likely to remember to take it) [25].
The necessity-concerns framework has also been found to predict both intentional and non-intentional
adherence in patients starting medication for a range of chronic illnesses [25].
Cardiac patients are particularly at risk in comparison to oncology or dialysis patients and they
are significantly more likely to perceive that the personal costs of their medication outweigh the
benefits [26]. When assessing medication benefits patients often consider whether their medication is
having an impact upon their symptoms [20]; since cardiac patients often present as asymptomatic, they
may not perceive their medication as a “necessity”. By emphasising the importance of, and the benefits
of, medication to cardiac, or in this case specifically to atrial fibrillation, patients, it may be possible to
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increase adherence. Further it seems pertinent to address any misconceptions surrounding the potential
harm of the medication prescribed. In order to improve adherence rates, patients must understand the
need for treatment and any concerns they have about taking it must be tackled. The intervention must
incorporate the needs and concerns of both unintentional and intentional non-adherers.
Table 1. Key recommendations regarding beliefs about medications.
Key Recommendations
‚ Address unintentional non-adherence by using reminders/memory aids/dosettes
‚ Address intentional non-adherence by discussing with the patient their individual barriers to adherence
and the benefits of their prescribed medication
‚ Discuss with patients the consequences of their illness, risks associated with treatment and how this
related to their perceived barriers to medication adherence
1.2.2. Application of the Common Sense Model
The “common sense model” (CSM) of illness perceptions suggests that patients’ appraisal of
somatic changes, such as symptoms, can explain both patient care seeking and management of
their condition [25–28]. For example, symptoms of illness may be attributed to ageing [29,30] or
psychological stress [31], thus not prompting treatment-seeking behaviours. Many patients may hold
medically unsupported beliefs about their medical condition, derived from the media, extreme cases,
lay-persons, or general beliefs about health and illness. The CSM suggests that patients rely on a set
of ‘mental tools’ to understand somatic stimuli such as duration, location and severity of symptoms.
For example, hypertension patients new to treatment were likely to drop-out of the regimen if they
construed the treatment as acute. However, those patients continuing treatment were more likely
to believe their medication was having beneficial effects upon their symptoms [20]. In adolescent
patients with type 1 diabetes, a change in perceived effectiveness of the diabetes treatment regimen
predicted dietary self-care [32]. Thus the patients’ beliefs about their illness and treatment regimen can
impact upon their uptake and maintenance of health behaviours. By understanding patients’ illness
representations we are able to understand how patients self-regulate their illness and their treatment.
This model has been used to predict treatment seeking, medication adherence and patients’ attribution
of symptoms [33,34], and has also informed successful interventions to aid management of chronic
illnesses [35,36].
The CSM describes five key components of patient illness representations: (i) identity—symptoms
associated with the specific illness and label ascribed to the illness; (ii) consequences—expected physical,
social and economic implications; (iii) timeline—acute, chronic or cyclical duration; (iv) causes—personal
beliefs about causes; and (v) cure/control—the extent to which a patient believes they will recover
from or control their illness [26,27,37,38]. McAndrew and colleagues focused on the use of CSM for
intervention design and suggested integrating the five components into an intervention and monitoring
the change between current status and the desired endpoint(s) [39].
Patients’ common sense models of their physical health and illness can be influenced by subjective
cognitions (particularly symptoms, moods, and experienced dysfunction). This symptom-focused
prototype can interfere with the successful management of their condition, particularly when patients
are asymptomatic, as they may use subjective cues (such as symptoms) to identify the illness. For AF
patients symptoms may come and go, or not occur at all, giving patients an inaccurate perception of
their illness identity. Thus it is important to provide patients with a top-down conceptual framework
for AF so that they can recognise that it is present even if they are asymptomatic (see Table 2).
An additional intervention component which replaces automatic control with volitional control
is needed within the intervention. This involves patients knowing what to do to minimise the
risk, thus controlling their health outcomes (e.g., dietary change, reducing alcohol intake and use of
anticoagulants) and relying on objective rather than subjective indicators (identity, using INR as a meter
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for control, rather than symptoms) to evaluate the efficacy of treatment (control and consequences) [28,39].
This approach focuses on behavioural change by using an action plan and/or diary. The volitional
control system can then be integrated into daily behaviour and will eventually become automatic [39].
Table 2. Summary of the requirements for patients to create a cognitive representation of AF.
Create an illness identity
Help patients understand which symptoms are/are not associated
with AF, common co-morbidities, the risks of stroke and the reasons
for prescribing anticoagulant medication and the emotions individuals
associate with the illness (e.g., “I am afraid of what will happen“).
Understand the consequences
Help patients understand the physical, social and economic
implications of both AF and treatment with anticoagulation. Patients
need to be provided with information about the risks associated with
AF e.g., the main risk associated with AF is stroke.
Identifying their illness timeline
Patients can be made aware of the duration of their illness and
treatment and given information about the different types of AF and
how this relates to the risk of stroke.
Understanding the causes Patients need to recognise their personal ideas about the causes of AFand how they relate to the scientific evidence.
Identifying a cure or control for
their illness/symptoms
Patients can be presented with information pertaining to the control of
their INR and pharmacological control of their AF symptoms, and
explore the factors that may affect their symptoms including caffeine
intake, exercise and alcohol. Of particular relevance are the key
lifestyle factors that affect INR control including diet, alcohol intake
and other medications and supplements, as for many patients there is
no “cure” for AF.
By eliciting concerns about treatment and prescribing a convenient treatment regimen tailored
to address practical barriers to adherence, patients may be more likely to manage their illness
effectively [39]. Patients are taught to become expert self-managers, formulating an action plan
to monitor their intake of foods that are high in vitamin K and thus affect INR control, alcohol intake,
and other medications and supplements. Generally INR monitoring is largely hospital-based and thus
not truly a self-monitoring process, however self-monitoring/self-management of warfarin is a viable
option for selected patients. Hence whilst patients can still develop action plans, they are not able to
use INR as an objective self-monitoring indicator. However, patients can reflect upon lifestyle factors
that influence their INR control by using a self-monitoring diary. This acts as a feedback-loop, allowing
patients bottom-up inputs (INR test results) to act as a monitor for control. Monitoring is often reduced
as the INR stabilises after the first few weeks, thus the diary can be used for the initial few weeks of
the treatment. Furthermore patients can create their own action plan specifically focusing on the areas
that they personally need to control, for example, some patients may feel their current alcohol, dietary
intake or vitamin supplements could cause problems for their INR control.
2. Experimental Section
2.1. Development of the Intervention Materials
The design of this intervention was aimed at being as explicit as possible to avoid “unseen” content
and to ensure it is replicable within a usual hospital care setting. We have described its components
using a taxonomy of behavioural change techniques defined as reliable and theory-derived [40].
2.2. Intervention Outline
The one-off, hour-long session was delivered to groups of 1-6 newly-diagnosed, warfarin-naïve
patients in a hospital setting. Patients took part in a discussion group; worksheet based activities,
and watched a DVD. Patients also took educational materials home including a booklet and
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self-monitoring INR and lifestyle diary. Each of the intervention components mapped onto the
theoretical framework and incorporated several behaviour-change techniques which are detailed
further in Table 3. An example of a behaviour change technique developed is to “provide information
on consequences”. By providing patients with the educational information about stroke risk and
treatment risks (such as bleeding), patients are able to create their own (accurate) perception of
their illness and its potential consequences. When completing the worksheet patients use a stroke
risk acronym (CHADS2 [41] score at the time of the intervention development (based on clinical
guidelines in 2009 [42]) but now the CHA2DS2-VASc score [43] would be used based on current clinical
guidelines [16–18]) to calculate their own risk of stroke, they also watch a DVD of other patients
discussing their own experiences of treatment (what happens if you adhere/do not adhere) and they
discuss the consequences of their illness and their experiences of those consequences (for example,
transient ischemic attack or stroke). Thus we used different methods (including DVD, worksheet,
and booklet) to provide education, ensuring the message was accessible. Table 3 documents the
educational components of the intervention and how these relate to theoretical models and behaviour
change techniques.
2.3. Patient Involvement
Once the theoretical basis for intervention development was established and appropriate
educational information had been gathered (based on clinical guidelines published by the National
Institute for Health and Care Excellence (NICE) [18], various presentation methods, such as detailed
explanations, diagrams, graphs, pie chart and pictograms (as derived from [44] were piloted with
AF patient groups. The key objective of the implementation study was to establish AF patients’
preferred communication methods for the educational information and to ensure the final materials
were patient-focussed and could be easily understood (using the “teach-back” method). Patients were
asked to relay the key message that the information was trying to convey, or to explain the information
to the researcher and/or the other participants. For this purpose two focus groups and six individual
interviews were carried out. The first focus group was exploratory, drawing on patient’s experiences
and perceptions of their illness and treatment and helped to inform the content of the educational
materials (booklet, DVD and patient narratives). This paper will draw on the second focus group
and the interview data. During this focus group, 6 warfarin-experienced patients with AF (3 males
and 3 females) were presented with information slides; the same information was also presented to
4 patients who were new to warfarin, within the interviews. During the focus groups patients came
to a consensus regarding which information and presentation styles to include. For the purpose of
this development paper, we will draw on some examples that illustrate patient involvement in the
intervention design.
2.3.1. Description of Symptoms
Patients were presented with a slide that described the symptoms associated with AF, taken
from a published article outlining associated symptoms [45]. They were asked whether this clearly
described the symptoms they attributed to their AF. Two key factors were raised. Firstly, some patients
are asymptomatic and felt this should be clearly stated within the materials. One male AF patient
stated: [M2]: “I can only say that on the last article on. . . .other people with atrial fibrillation, I had no symptoms
at all and it came about by a routine inspection and I believe that I told... when I say... symptoms I am talking
about the chest discomfort, the light headedness, the tiredness, or fainting... none of that”.
Secondly, for several patients their symptoms had previously been misattributed to other causes
and a clear list of symptoms clarified the identity of their illness, one female patient explains [F1]:
“when I first started experiencing palpitations and tiredness and slight shortage of breath... occasionally... I was
told that it was all part of erm... the work I was doing at the time and it was an occupational hazard.” Thus, a
clear list of symptoms is included in the intervention materials, noting that some patients may also
be asymptomatic.
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Table 3. Theoretical intervention components.
Behavioural Change Technique Method of Delivery Intervention Components Theoretical Model Targets
Provide general information on
behaviour-health link
‚ DVD (AF patients, cardiologist)
‚ Booklet
‚ Education on AF and OAC
‚ Advice on alcohol intake, diet and other
medications and supplements
‚ Risk information for stroke (with and
without medication)
‚ Risks of non-adherence
‚ Necessity-concerns
‚ Illness perceptions (Consequences,
timeline, causes)
Provide information on
consequences
‚ DVD (AF patient experiences of
bleeding/bruising)
‚ Worksheet (action plan,
risk calculations)
‚ Booklet (risk of stroke/side
effects percentages)
‚ Calculate their own risk of stroke using the
stroke risk tool
‚ Draft action plans to minimise this risk
‚ Presentation of risk of stroke and
bleeding complications
‚ Illness perceptions (identity)
‚ Necessity-concerns
‚ Illness perceptions (Consequences)
Prompt barrier identification ‚ Group discussion
‚ Worksheet questions
‚ Think about potential barriers to adhering
to recommendations
‚ Design a personal action plan to overcome
these barriers
‚ Discuss barriers that other patients have
identified and the ways in which they
made changes to overcome these barriers
‚ List the 3 main concerns about taking
warfarin; raise these concerns within the
group discussion, or talk to the researcher
following the session
‚ Necessity-concerns
‚ Illness perceptions (identity)
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Table 3. Cont.
Behavioural Change Technique Method of Delivery Intervention Components Theoretical Model Targets
Provide instruction
‚ DVD (Cardiologist)
‚ DVD (mock consultation)
‚ Booklet
‚ Informing the patient how to perform
specific health behaviours such as ‘what do
if you miss a dose of anticoagulation’, ‘how
to remember to take your tablets’, and
‘when to seek medical attention’
‚ Formulate a personal action plan which
will include memory aids for medication
and what to do in an emergency
‚ Unintentional non-adherence
Prompt self-monitoring
of behaviour ‚ Self-monitoring diary‚ Worksheet (Action plan)
‚ Keep a daily record of dietary intake,
alcohol units and medications and
supplements for a 2-week period
‚ Self-reflective tool to encourage patients to
assess what lifestyle changes may have had
an impact on their INR values
‚ Intentional non-adherence
‚ Necessity-concerns
‚ Illness perception
(Consequences & control)
Teach to use prompts/cues ‚ DVD (AF patients)
‚ Worksheet plan
‚ Patients are encouraged to identify
environmental prompts which can be used
to remind them to take their medication
‚ Group discussion of the roles of their
partner or family members within their
treatment regimen. Patients are
encouraged to discuss their own
memory-aid methods
‚ Intentional/unintentional
non-adherence
Provide opportunities for
social comparison ‚ DVD (AF patients)‚ Group discussion
‚ Delivery of intervention in a group setting
allows for social comparison
‚ Patient narratives from existing AF
patients taking warfarin, using the DVD
‚ Necessity-concerns
(unintentional-non adherence)
‚ Illness perception (Causes, controls
and consequences)
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2.3.2. Types of AF
Patients were presented with definitions of the different types of AF (see Box 1), they discussed
their understanding of the definitions, which category they fitted into and why.
Box 1. Classification of atrial fibrillation [18].
1. Paroxysmal: multiple episodes that typically last less than 48 h and stop by themselves.
2. Persistent: episodes that last longer than 7 days, or stop when treated.
3. Permanent: continuous atrial fibrillation for more than 1 year.
All of the patients appeared to be able to quickly categorise themselves (see dialogue below in
(Box 2), thus the descriptions were kept the same.
Box 2. Patient quotes surrounding definitions of AF.
[M2]: “out of that... number 3 will be the nearest to me... permanent continuous atrial fibrillation... for
more than 1 year and I would say 50 years... that's how long I can go back... I can only say its
number 3 for me because of the length of time”.
I – “how about everybody else?”
[F1]: “I have spent 3 years since I was diagnosed with it. With atrial fibrillation”
I– “and which category would you fall into?”
[F1:] “mmm I would say probably the first one... comes and goes...”
2.3.3. Risk Presentation
Patients were shown three different presentation methods for the same risk information.
The information related to the risks of stroke associated with AF and the risks of bleeding associated
with treatment with warfarin. Presentation methods included two traditional methods: pie charts, bar
charts and one more novel method, pictograms (denoting each percentage as a smiley face, previously
used as a decision making tool [44,46]). Patients were asked which method they preferred and which
they understood. All patients agreed that the pie chart presentation method was clearer for a range of
statistical risk information. One patient described how time-consuming the pictogram method was
[F1]: “because otherwise you are going to be sitting there ages as I say. . . counting how many faces are there on
there. . . whereas with the circle you got. . . straight away”. The pie chart presentation was adopted for the
presentation of risk information within the educational booklet (see Supplementary Figures).
2.3.4. Diagram of the Heart and Formation of Clots
Patients were presented with a diagram (of a torso and diagram of the heart, nervous system
and brain) describing the formation of clots within the left atrium (top chamber) of the heart and
the subsequent risk of stroke. They were asked whether the diagram was useful and whether they
understood information they were presented with. The dialogue indicated that this diagram provided
the informational link between the risk of blood clots and the risk of stroke (see Box 3).
Box 3. Patient quotes surrounding stroke torso diagram.
[F1]: “well its explaining what can happen in the sections of the heart and how erm, as it there, clots can
form and erm”
[M1]: “go to the brain”
[F1]: “yeah . . . can go to the brain and that can cause erm strokes or whatever and at the same time, it is
also showing how the different movements of the heart, the pumping of the heart”
[M1]: “oh yes”
[F1]: “can effect erm . . . this distribution shall we say unless it is controlled with a thinning . . . drug or
whatever. That’s how I look at it”
Healthcare 2016, 4, 10 10 of 17
Another patient described how the information provides an explanation for the need for
anticoagulation with warfarin [F2]- “it would help and it would help you to know why you have
been given your medication and what it was gonna do to help prevent you. . . you know having
the blood clot in first place”. The original diagram was digitalised and adapted for use within the
educational booklet.
3. Results
3.1. Evaluation of the Intervention
The intervention was evaluated in a randomised controlled trial comparing patients receiving
the intervention in addition to usual care (attendance at the hospital OAC clinic) with usual care
alone. The protocol for this trial has been published elsewhere [14], the trial is registered with
Current Controlled Trials [47] and the trial design is summarised in Table 4. There were no significant
differences between the groups at baseline on any of the demographic variables.
Table 4. Summary of the TREAT randomised controlled trial.
Trial No ISRCTN93952605
Target group
N Randomised: 46 intervention vs. 51 usual care
Diagnosis: Warfarin-naive AF patients
Demographics of cohort: Mean (SD) age 72.9 (8.2) years; 64.9% male; 99%
White British, Irish or European. No significant differences in demographic
variable between groups.
Inclusion/exclusion criteria: AF patients newly referred for warfarin therapy,
with ECG-documented AF, will be eligible for inclusion. Patients were
excluded if they were aged <18 years old, had any contraindication to
warfarin, had previously received warfarin, had valvular heart disease,
cognitively impaired, unable to speak or read English or had any disease
likely to cause their death within 12 months.
Intervention
Type: One-off group [1–6 patients] theory-driven educational intervention
Content: DVD, educational booklet, worksheet, group discussion.
Duration: 1 h session
Facilitator: Health-Psychologist (could be delivered by trained lay educator)
Setting: Hospital outpatients clinic
Outcomes
Primary outcome: Time within therapeutic range (TTR) calculated using the
Rosendaal method
Secondary outcomes: Patient knowledge, Beliefs about Medication, Quality
of Life, Anxiety and Depression, Hospital Admissions and Adverse events.
Comparison group Usual Hospital Care
Random sequence generation
A computer generated list stratified by (a) age (<70 and ě70 years)/sex and
(b) specialist AF clinic versus ‘general’ cardiology clinic, in blocks of four,
randomised patients on an individual basis to receive either ‘usual care’ or
the intensive educational intervention, in addition to ‘usual care’.
The randomisation schedule was designed by an independent trials unit.
Blinding
A researcher not involved in the data analysis or intervention delivery
matched patient ID numbers with randomisation codes and checked
follow-up questionnaires for completeness.
The researcher analysing the data was blinded to which arm of the
intervention patients were randomised to.
The findings of the randomised controlled trial which tested the TREAT intervention have been
published elsewhere [15]. In summary, the intervention group had a significantly higher proportion of
time in the therapeutic range (TTR) (a measure of anticoagulation control and medication regimen
adherence) at 6 months than the usual care group (76.2% vs. 73.1%; p = 0.035); these differences were
not significant at 12 months (76.0 vs. 70.0%, p = 0.44). However it is important to consider why and
how this intervention may have proved successful in its primary objective of improving TTR. The two
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theories that formed the basis of the intervention development were the beliefs about medication
theory and the common sense model for illness perceptions [20,27].
3.2. Beliefs about Medication
There were significant differences between intervention and usual care groups perception of
medication harm (F (1, 28) = 4.4; p < 0.05), the intervention group viewed the intervention as less
harmful than the usual care group [15]. There were no significant differences between groups on the
other subscales.
There was also a significant interaction between groups across time for perceived medication
harm (F (4, 28) = 2.4; p = 0.04), perceived general overuse of medication (F (4, 28) = 2.4, p = 0.04) and
concerns about medication (F (4, 27) = 2.9, p = 0.02), but no interaction for perceived necessity of
medication. There were no significant changes in scores on the subscales across time. The general
harm scores at 1 month was the only significant predictor of the 6-month TTR scores (F (1, 72) = 4.08,
p = 0.04) [15].
3.3. Illness Perceptions
Patients’ perception of the AF timeline (acute, chronic or cyclical) differed significantly across
time (F (4, 25) = 5.9; p < 0.01), but not between groups. Perceived treatment control (F (4, 25) = 2.7;
p = 0.05), emotional representation (F (4, 26) = 3.1; p = 0.04), and illness coherence scores changed
significantly over time (F (4, 26) = 4.6; p < 0.01), but not between groups. IPQ factors did not predict
TTR at 6 or 12 months [15].
There were no significant differences between groups across any of the illness perception questions
other than perceived cause (see Table 5). At baseline, the majority of patients thought that there was a
psychological cause (e.g., stress or bereavement; 41%), or an external cause of their illness (e.g., age
or previous morbidity; 31%); fewer blamed lifestyle factors (e.g., smoking, diet or lack of exercise;
29%). At the one month follow-up, more patients believed that there was an external cause of their
AF (48%), rather than a psychological cause (33%). At each follow-up, the intervention group was
more likely to perceive the cause as external, while patients in the usual care group were more likely to
perceive the cause of their AF as psychological. These differences were significant at 6 months (p = 0.04).
This indicates that patients did change their perception of cause after receiving the intervention.
4. Discussion
The results from this study give some insight into the mechanisms by which the intervention has
proved successful in improving patient INR control. Where patients viewed their medication as less
harmful, they were more likely to adhere to their medication, as reflected by their TTR scores, a finding
which supports previous evidence [25,30,31]. Thus patient’s perception of the ”toxicity“ of medications,
and their views surrounding the impact of side effects in the long- and short-term may have changed
as a result of the intervention. However, intervention design seldom considers the impact that
medications perceived by the patient as harmful will understandably have on medication adherence.
When deciding whether or not to initiate new medication a patient undertakes an individual
risk-benefit assessment [32], this process is important as treatment choices carry significant risks to
patient safety if the guidelines and lifestyle recommendations are not adhered to. Their ability to do
this is dependent on assimilating information about the risk of stroke conferred by AF against the risk
of bleeding associated with warfarin, a process which cannot take place accurately without appropriate
education and delivery of information (educational tools).
Both groups scored highly on the specific-necessity subscale at all time-points, suggesting that all
patients within the trial viewed their medication for AF as highly necessary. However, patients in the
intervention group were less concerned about their medication at all time-points. The greater difference
between necessity and concerns scores in the intervention group, suggests patients perceptions about
the necessity for warfarin outweighed their concerns about taking it. Evidently AF patients view the
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reduction of stroke risk, and subsequently the need for treatment, as more important than the potential
bleeding risks associated with warfarin. This also supports evidence surrounding patients’ perceptions
of warfarin and their willingness to accept bleeding risks in order to reduce their risks of suffering
from a stroke [46,48,49].
The present findings suggest that there were no significant differences between groups across
any of the illness perception questions other than perceived cause. This contradicts previous evidence
where interventions using the principles of the common sense model have found changes in illness
perceptions [35,36]. However, previous studies have used a more individualised intervention approach;
assessing unique illness perceptions, and targeting specific problematic areas [35,36]. Thus, the TREAT
intervention, which aims to be accessible for the lay educator within usual hospital care, and generic
in its approach, may not have the same impact, but rather help to prevent the formation of inaccurate
illness representations.
Patients in the intervention group had a more accurate perception of their illness following the
intervention, stating established causal factors including age, male gender, hypertension, valvular
heart disease, heart failure, coronary artery disease, diabetes, [16–18,50,51] and genetic factors [52,53].
AF patients have previously reported psychological causes of AF [13], despite evidence to the contrary;
which could contribute to the emotional burden of their illness. Changing lifestyle factors represents
an area patients are able to control, as opposed to external factors such as age, or other co-morbidities.
This change in perceived causality may have impacted upon the patients’ perceived control over their
illness and treatment.
Using the IPQ-B as an evaluation tool has its limitations. It does not assess patients’ perception of
the cyclic nature of their illness. Previous evidence suggests AF patients view their illness as cyclic
rather than long-term [13]. However, McCabe and colleagues had a higher percentage of symptomatic
paroxysmal patients (64%) in their study, thus the results may be affected by the differences between
samples. The validity of the IPQ-B has been deliberated in a recent article [54]. Thus, it is possible that
some of the differences between groups were not identified due to poor sensitivity of this tool.
Patients in the intervention group achieved a significantly greater proportion of TTR after
6-months of warfarin than patients receiving usual care alone [15]. However, 12-months after initiating
warfarin there was no significant difference in TTR between the groups although TTR was higher in the
intervention group [15]. Therefore, patients with chronic conditions which require life-long adherence
to medication and lifestyle modification, as with AF, may require interventions such as TREAT to be
repeated at regular intervals in order to refresh information and reinforce behavioural changes.
Whilst patients are often encouraged to adhere to treatment recommendations, general
practitioners and physicians rarely discuss the behaviours required to become adherent and perceived
treatment barriers [55,56], thus interventions are not tailored to patient’s needs. The TREAT
intervention was a collaborative project between patients, the theoretical approaches of health
psychologists, and the clinical guidance of cardiologists and existing clinical guidelines [3,16–18,57].
The successful management of chronic illness is a multidisciplinary process, which integrates the
patient and their beliefs into every aspect of clinical care. We hope that by documenting this process,
other researchers will benefit in the future when designing complex interventions.
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Table 5. Patients’ perceived cause of atrial fibrillation.
N (%) Baseline χ2 1 Month χ2 2 Months χ2 6 Months χ2
Intervention
(n = 25)
Usual care
(n = 34)
Intervention
(n = 24)
Usual care
(n = 24)
Intervention
(n = 19)
Usual care
(n = 19)
Intervention
(n = 23)
Usual care
(n = 21)
Psychological 10 (40.0) 14 (41.2) 1.38 8 (33.3) 8 (33.3) 0.15 3 (15.8) 9 (47.4) 4.47 3 (13.0) 9 (42.9) 6.31 *
External 6 (24.0) 12 (35.3) 11 (45.8) 12 (50.0) 12 (63.2) 8 (42.1) 17 (73.9) 8 (38.1)
Lifestyle 9 (36.0) 8 (23.5) 5 (20.8) 4 (16.7) 4 (21.1) 2 (10.5) 3 (!3.0) 4 (19.0)
* p < 0.05; psychological: includes answers relating to psychological morbidity including stress, anxiety, depression and bereavement; lifestyle: includes factors related to patients
lifestyle habits such as smoking, excess drinking, obesity and excessive exercise; externals: includes factors that patients cannot control including hereditary disposition, following
surgery or other chronic illness.
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5. Conclusions
Complex interventions for use with patient health behaviours need to be theory driven and based
on relevant current literature and clinical guidelines. The success of an intervention relies on patient
involvement. The TREAT intervention changed patient beliefs surrounding their treatment necessity
and treatment harm. We used several behavioural-change techniques to relay these messages, but
the most powerful messages were the lived experiences of the AF patients themselves, presented
as narratives on the DVD. As healthcare professionals we cannot assume patients understand the
necessity of their medication and we cannot underestimate the impact of individual perceptions of
medication and illness on the management of a chronic illness.
Practice Implications
Future researchers and healthcare workers aiming to develop patient interventions need to be
explicit about the content and theoretical components to enable replication of successful interventions.
Interventions for patients with AF starting warfarin should include the following key elements to
enable behaviour change:
‚ Provide educational materials and discuss the health-behaviour link, enabling patients to
understand why and how they make lifestyle changes.
‚ Provide educational materials and risk information on the consequences of AF and treatment
with/or without warfarin
‚ Provide opportunities for social comparison with other patients
‚ Encourage patients to self-monitor, create action plans, and use their own memory aids/cues for
remembering to take tablets
‚ Discuss patients concerns and barriers to changing their lifestyle and adopting a new treatment
regime; correct any misconceptions with accurate information.
Presenting the full methodology behind the development of interventions could enable
intervention design to become a much more efficient and transparent process.
Supplementary Materials: Supplementary Figures S1–S4 are available online at http://www.mdpi.com/
2227-9032/4/1/10/s1.
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